

Immunization Schedules for U.S.-Bound Refugees administered by the International Organization for Migration (IOM)^a Nov 2013
Prepared by Immigrant, Refugee and Migrant Health Branch, Division of Global Migration and Quarantine, CDC

This table describes the immunization schedule for US-bound refugees, and includes vaccines given as part of the new CDC-PRM expanded immunization program in Kenya, Ethiopia, Thailand, Malaysia and Nepal (shaded boxes). As part of this program:

- Refugees will receive up to 2-3 doses of a vaccine series based on time before departure. However, IOM will take previous vaccine history into account if reliable and available.
- First doses of all vaccines are given at the overseas medical screening exam, approximately 2-6 months before departure for most refugees.
- Most second doses of vaccine are given 2 months after the first dose.
- Refugees whose medical examination validity expires due to delayed departure (> 3-6 mos depending on the presence of Class B1 condition) may receive additional doses of vaccine.
- No routine vaccines will be administered by IOM within 2 weeks prior to departure except in special outbreak settings. CDC will provide additional notification during these situations.

Region/Country	Vaccines Given to Eligible Refugees in All Listed Countries		Comments
	Age	Vaccines ³	
Ethiopia ¹ (started Nov 2013)	Birth-adult	HepB x2	<u>General</u> IOM will attempt to complete the series of each vaccine shown in the previous column if time permits <u>Pentavalent vaccine</u> <ul style="list-style-type: none"> • 2nd dose in urban refugees only, and given up to 15 mos of age. <u>Polio vaccine</u> <ul style="list-style-type: none"> • tOPV (virus types 1, 2, 3) is used in all countries except Kenya and Malaysia, and counts towards U.S. polio vaccine requirements. • In Kenya, bOPV (virus types 1, 2) is currently used due to an ongoing polio outbreak. bOPV does not count towards routine U.S. polio vaccine requirements.
Kenya ² (started Sept 2013)	6 wks-<5 yrs	Pentavalent (DTP,Hib,HepB) x 2	
Malaysia (started May 2013)	5 yrs -<7 yrs	DTP ⁴ x 2 (2 nd dose in urban refugees only)	
Nepal (started Dec 2012)	6 wks-<11 yrs	tOPV x 2 doses bOPV x 3 doses (Kenya only)	
Thailand (started Dec 2012)	6 wks -<7 yrs	IPV (Malaysia only) x2	

	<p>7 yrs-adult</p> <p>≥ 1 yr-born ≥ 1957</p>	<p>Td x1</p> <p>MMR x2</p>	<ul style="list-style-type: none"> When IPV becomes available for older children in Malaysia, it will be administered for children up to 11 years of age. IPV counts towards U.S. polio vaccine requirements. <p><u>MMR vaccine</u></p> <ul style="list-style-type: none"> Administration of a 2nd dose of MMR began in March 2011 in Kenya, Sept. 2011 in Malaysia, and January 2013 in Ethiopia. In Malaysia, from Sept 2011 to Feb 2013, children 6-11 mos received 1 dose of MMR as part of a measles outbreak response. <p><u>PCV-13 vaccine</u></p> <ul style="list-style-type: none"> <i>When available, PCV-13 will be given to children 6 wks -<5 yrs of age. A second dose will be given to children up to age 2 yrs. One dose of PCV-13 will also be given to all immunocompromised persons aged 5 yrs and older.</i>
Tanzania	<p>≥ 1 yr - Born ≥ 1957</p>	MMR x1	One dose of MMR is administered at time of initial health assessment (approximately 2-6 months before arrival in U.S.)

¹ Principal refugee groups from Ethiopia include Eritreans (Shimelba camp); Somalis (Kebribeya camp); Multiple (Addis Ababa)

² Principal refugee groups from Kenya include Somalis (Dadaab camps); Somalis, Sudanese, Congolese (Kakuma camp); Multiple (Nairobi)

³ MMR= measles, mumps, rubella; bOPV= bivalent (types 1 and 2) oral polio vaccine; tOPV= trivalent (types 1, 2 and 3) Hep B=hepatitis b; DTP= diphtheria, tetanus, pertussis; Hib= Haemophilus influenza b

⁴ Dose #2 DTP for children 15 mos-7 yrs residing in urban areas only. Children residing in refugees camps often receive DTP as part of routine vaccination by the camp health care provider. As part of the resettlement vaccination program, these children will receive only 1 dose of DTP or pentavalent (DTP-Hib-HepB) from IOM in order to reduce the risk of adverse local reaction due to over-vaccination with DTP.